Adult T-cell leukemia (ATL) is caused by human T-cell lymphotropic virus I and is an aggressive malignancy of CD4, CD25 expressing leukemia and lymphoma cells.
Introduction
Adult T-cell leukemia (ATL) is an aggressive malignancy of mature activated CD4 + Tcells associated with human T-cell lymphotropic virus type 1 (HTLV-1) infection [1] [2] [3] . The leukemic cells are characterized by the expression of interleukin-2 receptor α (IL-2Rα, CD25) on their cell surfaces [4] [5] [6] . At present, there is no accepted curative therapy for ATL and the patients progress to death with a median survival duration of 9 months in acute ATL and 24 months in chronic ATL 7 . A preclinical in vivo murine model of ATL was developed by introducing leukemic cells (Met-1) from a patient with ATL into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice 8 . New therapeutic approaches have been tested in this model before initiating human clinical trials 9, 10 .
Daclizumab (Zenapax TM ), A monoclonal antibody targeted at the IL-2Rα (CD25) showed excellent therapeutic efficacy in this murine model 8 . In clinical trials, it has also yielded some partial or rare complete remissions in patients with ATL, suggesting that this new IL-2Rα targeting monoclonal antibody therapy is promising in the treatment of patients with ATL. Recently, a high response rate following azidothymidine/ interferon α (AZT/IFN α ) treatment of ATL patients has been reported in several human trials (11) (12) (13) ).
The tumor suppresser p53 appears to be a predictive marker for AZT response as patients responded to AZT therapy only when p53 was wild type in sequence, and inversely disease relapse or absence of response was associated with mutation and inactive p53 14 .
A paradigm has emerged that the combination of a monoclonal antibody with chemotherapeutic reagents that function via different mechanisms of action may be greater than additive in their cytotoxic action leading to malignant cell death. Thus, it will
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Histone deacetylase (HDAC) inhibitors are a new class of anti-tumor agents which are currently undergoing intensive pre-clinical and clinical testing. HDAC inhibitors are potent inducers of apoptosis and growth inhibition with a variety of transformed cells in vitro and in vivo, including malignancies originating from lymphoid cells [15] [16] [17] .
Depsipeptide (FR901228, FK228), isolated from Chronobacterium violaceum, is a member of the cyclic peptide class of HDAC inhibitors. Depsipeptide has shown cytotoxic effects on a number of malignant lymphoid cell lines 18 including HTLV-1
infected T-cell lines 19 . Depsipeptide is currently in clinical trials for evaluation of its anticancer efficacy 20 . Recent results using FR901228 in patients with cutaneous and peripheral T-cell lymphoma suggest significant activity in these diseases 15 . Furthermore, the study shows that the IL-2Rα expression level on the patients' malignant cells after depsipeptide treatment is increased. Based on these findings, it has been speculated that the combination of depsipeptide with IL-2Rα targeting therapy may enhance the antitumor efficacy of depsipeptide 15,21 . As discussed above, daclizumab is an IL-2Ra targeting agent. Thus, the combination of depsipeptide with daclizumab in the treatment of T cell malignancy could enhance the anti-tumor efficacy not only through two different modes of killing, but also through enhancing the expression of the target of daclizumab.
In this study, we investigated the therapeutic efficacy of depsipeptide alone and its combination with daclizumab in a murine model of ATL. Both depsipeptide and The assay was performed in triplicate and repeated 3 times.
Annexin-V staining and apoptosis analysis
Quantification of apoptosis was performed by immunostaining cells with Annexin-V, which specifically detects phospholipid phosphatidylserine (PS) redistributed from the inner to the outer leaflet during apoptosis 23, 24 . Cells cultured with 2ng/ml depsipeptide or media for 24 and 48 hours were labeled with Annexin V-FITC and subsequently analyzed by flow cytometry (FACS). The dead cells were labeled by propidium iodide (PI).
Caspase-3 and caspase-9 activity assay
The caspase-3 and caspase-9 activities were measured using caspase-3 and caspase-9 colorimetric assays from R&D systems (Minneapolis, MN). The activity was expressed as fold increase in depsipeptide treated cells over that of non-treated cells. The background values were subtracted from the experimental results prior to calculating the fold induction.
Western Blot Analysis
Treated cells were solubilized at 4°C in RIPA lysis buffer (50mM Tris-CL, pH7.4, 0.5% sodium deoxycholate, 1% Nonidet P-40, 150mM NaCl, 66-µg/ml aprotinin, 100-µg/ml phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate). Cell lysates (50 µg) were resolved by electrophoresis on SDS-polyacrylamide (4-12%) gels and transferred to 
Mouse model of ATL
The ATL cell population, MET-1, was established from the peripheral blood of a patient with acute ATL and the cells were maintained by serial transfer in NOD/SCID mice (Jackson Laboratories, Bar Harbor, ME). MET-1 cells have a distinct phenotype elucidated by fluorescein-activating cell sorting (FACS) analysis: CD3 dim , CD4 +/-, CD7 -, CD20 -, and CD25 + . The leukemia model was established by intraperitoneal injection of 1.5 x 10 7 MET-1 cells into NOD/SCID mice as described previously 8 . The therapy experiments were performed on these mice when their serum soluble IL-2Rα (sIL-2Rα) levels were more than 1000 pg/mL, which occurs approximately 10 to 14 days after tumor inoculation. All animal experiments were performed in accordance with National Institutes of Health Animal Care and Use Committee guidelines.
Definition of the maximum tolerated dose
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Prior to the initiation of the therapeutic studies, the maximum tolerated dose of depsipeptide was determined in NOD/SCID mice. Doses of 0.125, 0.25, 0.5, 1.0, and 2.0 mg depsipeptide per kg body weight were administered intraperitoneally daily for two weeks. All mice in 2.0mg/kg group died at day 7 and 80% of the mice in 1.0mg/kg group died at day 14. The mice in the 0.5, 0.25 and 0.125 mg/kg group were still alive six months after depsipeptide injection. Therefore, a dose of 0.5 mg/kg every other day for 14 days was chosen to use in the therapeutic trials and the dose is consistent with what people have used in mice 19, 25 .
Therapy study
Therapeutic studies were performed in MET-1 leukemia-bearing mice with serum surrogate tumor marker sIL-2Rα values of 1000 -10, 000 pg/mL in the small tumor burden trial and 10,000 -25,000 pg/ml in the large tumor burden trial. There were 5 groups in the therapeutic trials. Group 1, the depsipeptide group, received intraperitoneal injections of 0.5 mg depsipeptide/kg body weight every other day for two weeks. Group 2, the immunotherapy (daclizumab) group, was given intravenous injections of 100 µg daclizumab on days 0, 7, 14, and 21. Group 3, the combination therapy group, received a combined therapy of depsipeptide and daclizumab (dosing schedule as in group 1 plus group 2). Group 4 received 200 µL PBS weekly for 4 weeks served as a control. Group 5,  with no tumor and no therapy and served as a control for the natural death of NOD/SCID mouse. There were 13 mice per group in the small tumor burden therapeutic trial(sIL-2Rα, 1,000 -10,000 pg/ml); and there were 8 mice per group in the large tumor burden trial (sIL-2Rα, 10,000 -25,000pg/ml). The groups were randomly assigned and had comparable average levels of the surrogate tumor marker, sIL-2Rα, at the beginning of the experiments.
Monitoring of tumor growth
Measurements of the serum concentrations of the soluble IL-2Rα or soluble β 2microglobulin (β 2 µ) were performed using enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). The ELISAs were performed following the manufacturer's recommendation.
Statistical analysis
The serum levels of human sIL-2Rα and β 2 µ were analyzed at different time points for the different treatment groups using the Student t test for unpaired data. Statistical significance of differences in survival of mice in different groups was determined by the log-rank test using the StatView program (Abacus Concepts, Berkeley, CA). (Fig.3) , and on the survival of leukemia-bearing mice (sIL-2Rα, 1,000 to 10,000 pg/ml) ( Fig.4) . When compared with the serum concentration of sIL-2Ra and β 2 µ in the PBS control group of mice at 8 weeks post therapy, there was a significant reduction of sIL-2Ra as well as (Fig.4) .
Results

Depsipeptide inhibited the proliferation and induced apoptosis in
Furthermore, the mice in the treatment groups had much less infiltration in the lungs, liver and spleen but had tumor outgrowth subcutaneously when examined at the endpoint.
This may be due to incomplete saturation of the IL-2 receptor by daclizumab in the skin For personal use only. on October 24, 2017. by guest www.bloodjournal.org From as compared to blood or lymph nodes where the receptor is easily saturated as observed with patients with ATL (Dr. Waldmann, unpublished data). All the mice in the PBS group died before day 63 post therapy. However, at 120 days post therapy, 2 out of 13 mice in the depsipeptide treatment alone and daclizumab treatment alone groups and 13 out of 13 mice in the combination therapy group were still alive. The combination of depsipeptide and daclizumab treatment significantly prolonged the survival of leukemia bearing mice when compared with depsipeptide treatment alone (P<0.001) or daclizumab treatment alone (P<0.0001). 7 out of 13 mice survived more than 200 days in the combination group (Fig. 4) .
The Larger Tumor Burden Treatment Trial in the Met-1 Model.
The tumor burden was triple that of the small tumor burden group (sIL-2Rα, 10,000 to 25,000 pg/ml). The treatment of depsipeptide and daclizumab (same dose and dosing schedule as the small tumor burden trial) alone, and the combination of these two agents demonstrated therapeutic efficacy. The serum levels of tumor marker soluble IL-2Ra and β 2 u in the depspeptide group, daclizumab group and the combination group was significantly lower than that of the PBS group at 4 weeks post therapy (data not shown).
All three treatments significantly prolonged the survival of tumor bearing mice (P<0.0001). Furthermore, the combination of depsipeptide with daclizumab significantly prolonged the survival of the tumor bearing mice when compared with depsipeptide alone (P<0.01) or daclizumab alone (P<0.05). Similar to the small tumor burden trial, the mice in the PBS group had extensive infiltrations of leukemic cells in the lungs, liver and spleen. While the mice in the treatment group had much less infiltration in the lungs, liver
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From and spleen but had tumor outgrowth subcutaneously. The mice in the PBS group died before day 45 post therapy. However, at day 100 post therapy, 1 out of 8 mice in the depsipeptide treatment alone group, 2 out of 8 mice in the daclizumab treatment alone group were still alive. Furthermore, 5 out of 8 mice in the combination therapy group survived more than 180 days (Fig.5 ).
Discussion
The MET-1 ATL model presents many features that parallel those observed in patients with adult T-cell leukemia and thus represents a valuable model for the evaluation of the efficacy of therapeutic agents directed toward ATL 8 . In earlier studies daclizumab showed efficacy both in the MET-1 ATL model and in human clinical trials. In the human study, therapy with the umodified murine version of anti-Tac provided effective therapy for 6 of 19 patients with ATL studied 33 . There are two modes of tumor killing manifested by the monoclonal antibody daclizumab. One is the blockade of the binding of IL-2 to its receptor (IL-2Rα), as shown in patients with smoldering ATL, therefore leading to cytokine-deprivation induced apoptosis 33 . Another mode is antibody dependent cellular cytotoxicity (ADCC), as shown in murine Met-1 model, which requires the expression of FcRγIII on monocytes and granulocytes 34 . Daclizumab provides no therapeutic efficacy in the murine ATL model when examined in FcRγ knockout (FcRγ-/-) mice that do not express FcRγIII 34 . Recently, another mechanism of action has been reported. In particular, in humans the interaction of daclizumab with the IL-2 receptor alpha subunit was associated with a 4-to 20-fold increase in the number of circulating CD56 bright , CD25 expressing, IL-10 secreting natural killer cells that mediate negative For personal use only. on October 24, 2017. by guest www.bloodjournal.org From immuno-regulatory actions 35, 36 . A number of approaches could be exploited to optimize the action of daclizumab in the therapy of leukemias and lymphomas. A paradigm is being established that monoclonal antibodies will not be used ultimately in monotherapy of human malignancy, but rather will be used in association with an array of agents including chemotherapeutic agents that manifest a different mode of action. In the MET- the cyclic tetrapeptides, such as trapoxin A; and the bicyclic depsipeptides, such as depsipeptide. Among them, Vorinostat (SAHA) has been approved by FDA as monotherapy for cutaneous T cell lymphoma. In addition, Depsipeptide has shown major responses in the treatment of leukemia and lymphomas. Similar to other HDAC inhibitors, depsipeptide has been shown to induce cell cycle arrest, cellular differentiation, and apoptosis 16 . Although the precise mechanism of cell growth arrest, cellular differentiation and apoptosis is not clear; it is commonly accepted that depsipeptide exerts its anti-tumor effect via modulation of the expression and functions of cell cycle regulators and For personal use only. on October 24, 2017. by guest www.bloodjournal.org From apoptosis related molecules 16 . The molecular changes induced by depsipeptde include increased expression of p21 38 , altered expression of cyclins, hyperphosphorylation of Rb 38 , and decreased expression of c-myc in fibroblasts and in a T-cell hybridoma 39 .
Consistent with this, we observed that depsipeptide induced increased expression of p21, decreased expression of cyclin A and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-X L in HTLV-I infected T-cell lines.
Besides its anti-tumor effects, depsipeptide has been shown to be able to induce the expression of IL-2Rα, the target of daclizumab, both in cell lines 21 and in the patients with T cell lymphoma 15 . We reasoned that depsipeptide which was reported to be an Il-2Rα inducing agent might augment the acitivity of daclizumab, the combination of depsipeptide with daclizumab may improve the efficacy of daclizumab in the treatment of ATL. Indeed, in our Met-1 model of ATL, we observed greater efficacy for the combination of depsipeptide with daclizumab. When administered i.p. at 0.5mg/kg every other day for two weeks, the tumor growth was significantly inhibited and the survival of the mice was significantly prolonged in the combination group when compared with those in either the daclizumab or depsipeptide groups alone( Fig.4 &5) . However, in our study depsipeptide treatment did not increase the expression of IL-2Ra in HTLV-1 infected cell lines (data not shown). This suggested that the synergistic effect between depsipeptide and daclizumab was probably due to the combined effects of monoclonal antibody targeted therapy with a chemotherapeutic molecule, agents that act through different modes of tumor killing. As discussed above, the cytotoxicity of despeptide is induced by modulation of genes involved in cell cycle regulation and apoptosis 40 . On the other hand, the monoclonal antibody daclizumab, does not act through blockade of the For personal use only. on October 24, 2017. by guest www.bloodjournal.org From IL-2/IL2Ra autocrine loop in the Met-1 ATL model since the leukemic cells do not produce IL-2, nor do they express IL-2 mRNA. In addition, they do not proliferate in response to murine IL-2 8 . Depsipeptide treatment did not induce the expression of IL-2 either (data not shown). The immunoglobulin-Fc receptor does appear to be the major element involved in the action of daclizumab as daclizumab lost its therapeutic efficacy in the FcRγIII deficient mice 34 . However, depsipeptide treatment had no effect on FcRγIII expression in NOD/SCID mice (data not shown). This suggests that the synergistic effect of depsipeptide with daclizumab was not due to increased FcRγIII expression.
Currently, depsipeptide is in the phase II trial with cutaneous and pheripheral T cell lymphoma. Electrocardiogram abnormalities, thought to be a class effect associated with HADC inhibitors, were observed both in preclinical animal studies and in phase I testing of depsipeptide 41 . However, extensive cardiac studies in the phase II trial of depsipetide in T cell lymphoma concluded that the administration of depsipeptide was not associated with myocardial damage or impaired cardiac function 42 . The potential effect of heart ratecorrected QT interval prolongation remains under study. With significant clinical benefit in patients with cutaneous and peripheral T cell lymphoma, this safety data could further support the use of depsipeptide in patients with leukemias and lymphomas.
In conclusion, our data showed that depsipeptide had an anti-tumor effect both in vitro and in vivo. The combination therapy of depsipetide with daclizumab had significant synergistic therapeutic effect in the murine model of ATL. The results of our study For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 
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